Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder
- PMID: 11115562
- DOI: 10.3892/or.8.1.9
Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder
Abstract
It is generally accepted that there are dichotomous biologic pathways that lead to the development of either: i) superficial papillary (Ta) transitional cell carcinoma (TCC) or ii) precursor lesions to muscle-invasive (CIS, T1) TCC and muscle-invasive (> or =T2) TCC. We investigated the expression of several progression-related genes to characterize the phenotype of these tumors within these divergent developmental pathways. Using a colorimetric in situ hybridization technique, we examined the expression of mRNAs of several progression-related genes in archival, pathologic specimens from 77 patients with bladder TCC. These genes included basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), interleukin (IL)-8, matrix metalloproteinase (MMP)-9, and epidermal growth factor receptor (EGFR). Relative gene expression was quantified using image analysis. Gene expression was normalized using poly (dT) and the expression of each factor in a panel of specimens of normal urothelium. Patients were stratified according to disease stage, and the level of gene expression among the stratified groups was compared. VEGF, bFGF, IL-8, and MMP-9 expression was increased in muscle-invasive compared with superficial papillary tumors, (p<0.05) and VEGF expression was increased in muscle-invasive tumors compared with CIS specimens (p<0. 05). bFGF, IL-8, and EGFR expression was increased in CIS specimens compared with superficial papillary tumors (p<0.05). The pattern of expression of bFGF, VEGF, IL-8, MMP-9, and EGFR represent the divergent developmental pathways in the pathogenesis of bladder TCC, which characterizes superficial or invasive bladder cancer. bFGF, IL-8, and EGFR appear to be upregulated in early precursor lesions (CIS), whereas VEGF appears to be upregulated at later stages in the development of muscle-invasive TCC.
Similar articles
-
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.Clin Cancer Res. 2001 Sep;7(9):2840-53. Clin Cancer Res. 2001. PMID: 11555602
-
Identification of genes correlated with early-stage bladder cancer progression.Cancer Prev Res (Phila). 2010 Jun;3(6):776-86. doi: 10.1158/1940-6207.CAPR-09-0189. Epub 2010 May 25. Cancer Prev Res (Phila). 2010. PMID: 20501863 Free PMC article.
-
Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder.Urol Oncol. 2002 Mar-Apr;7(2):67-72. doi: 10.1016/s1078-1439(01)00153-3. Urol Oncol. 2002. PMID: 12474525
-
Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression.Urol Clin North Am. 2000 Feb;27(1):191-7. doi: 10.1016/s0094-0143(05)70247-0. Urol Clin North Am. 2000. PMID: 10696258 Review.
-
[Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].Verh Dtsch Ges Pathol. 1993;77:241-6. Verh Dtsch Ges Pathol. 1993. PMID: 7511289 Review. German.
Cited by
-
State-of-the-art management of metastatic disease at initial presentation or recurrence.World J Urol. 2006 Nov;24(5):543-56. doi: 10.1007/s00345-006-0115-x. World J Urol. 2006. PMID: 17031652 Review.
-
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.Cancer Metastasis Rev. 2009 Dec;28(3-4):335-44. doi: 10.1007/s10555-009-9194-7. Cancer Metastasis Rev. 2009. PMID: 20012924 Free PMC article. Review.
-
Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.Urol Oncol. 2021 May;39(5):301.e17-301.e28. doi: 10.1016/j.urolonc.2021.01.021. Epub 2021 Feb 7. Urol Oncol. 2021. PMID: 33563539 Free PMC article.
-
Targeted therapies in the management of metastatic bladder cancer.Biologics. 2007 Dec;1(4):393-406. Biologics. 2007. PMID: 19707309 Free PMC article.
-
Targeting angiogenesis in bladder cancer.Curr Oncol Rep. 2009 May;11(3):244-9. doi: 10.1007/s11912-009-0034-2. Curr Oncol Rep. 2009. PMID: 19336017 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous